Epcoritamab + Chemotherapy for Burkitt Lymphoma

This trial tests a new combination of treatments for individuals with high-risk Burkitt lymphoma, a fast-growing cancer. It combines epcoritamab, which aids the immune system in attacking cancer cells, with a chemotherapy regimen known as DA-EPOCH-R. The trial aims to determine if this combination is more effective at treating the cancer than chemotherapy alone. Individuals with Burkitt lymphoma and certain high-risk factors, such as large tumors or cancer in the bone marrow, might be suitable candidates for this trial. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants, offering a chance to benefit from potentially more effective therapy.

Research has shown that epcoritamab is generally safe for patients. Studies involving those with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) indicate it is usually well-tolerated. Most side effects, such as cytokine release syndrome (a reaction where the immune system releases too many proteins into the blood too quickly) and neurological events, are mild and manageable.

The chemotherapy treatment DA-EPOCH-R, which includes drugs like vincristine and doxorubicin, has a well-documented safety record. Patients often experience side effects like tiredness, nausea, and reduced blood cell counts, but these are expected and can usually be managed with medical help.

Researchers are excited about these treatments because they include epcoritamab, a novel antibody therapy that targets and kills cancer cells in Burkitt Lymphoma. Unlike standard treatments like R-CHOP, which rely solely on chemotherapy and rituximab, epcoritamab offers a new mechanism by specifically engaging the immune system to attack the cancer cells. Additionally, epcoritamab is administered subcutaneously, which can be more convenient and potentially less taxing on the patient compared to traditional intravenous methods. This combination of targeted action and easier administration makes it a promising addition to existing therapies.

Research has shown that epcoritamab, when combined with chemotherapy, yields promising results for treating high-risk Burkitt lymphoma. In this trial, participants in Cohort 1 and Cohort 2 Arm II will receive the combination of epcoritamab and DA-EPOCH-R chemotherapy. Earlier studies of this combination treatment reported an overall response rate of 87%, with 65% of patients experiencing a complete response, meaning their cancer disappeared. Epcoritamab attaches to certain proteins on white blood cells, aiding the immune system in identifying and destroying cancer cells. This suggests that epcoritamab could be a valuable addition to the usual chemotherapy treatment for this aggressive type of lymphoma.⁴⁶⁷⁸⁹